Granulocyte-Macrophage colony-Stimulating factor receptor-Targeted therapy of chemotherapy- and radiation-Resistant human myeloid leukemias
| Autor: | Kevin G. Waddick, Stella M. Davies, Berta Warman, Anne Bendel, Yu Shao, Chang H. Yang, Mridula Chandan-Langlie, Fatih M. Uckun, John P. Perentesis |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cancer Research
Myeloid Recombinant Fusion Proteins medicine.medical_treatment Antineoplastic Agents Biology Radiation Tolerance Targeted therapy Fusion Toxin hemic and lymphatic diseases Granulocyte macrophage colony-stimulating factor receptor Tumor Cells Cultured medicine Humans Cytotoxic T cell Diphtheria Toxin Progenitor cell Stem Cells Myeloid leukemia Hematology medicine.anatomical_structure Oncology Drug Resistance Neoplasm Leukemia Myeloid Receptors Granulocyte-Macrophage Colony-Stimulating Factor Cancer research Drug Screening Assays Antitumor Stem cell |
| Zdroj: | Leukemia & Lymphoma. 25:247-256 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Contemporary therapies for acute myeloid leukemia (AML) commonly fail to cure patients because of the emergence of drug resistance. Drug resistance in AML is multifactorial but can be associated with the overexpression of transmembrane transporter molecules, including P-glycoprotein (Pgp) or the multidrug resistance-associated protein (MRP), or associated with inactivation of the p53 tumor suppressor gene, as well as overexpression of the anti-apoptotic protein bcl-2. We are investigating if novel recombinant biotherapeutics can circumvent these resistance mechanisms to effectively treat refractory AML. To target the lethal action of diphtheria toxin (DT) to high affinity granulocyte-macrophage colony-stimulating factor (GMCSF) receptors on AML blasts, we have produced a recombinant chimeric fusion toxin, DTctGMCSF. Since DTctGMCSF enters and kills its target cells by unique mechanisms (GMCSF-receptor binding and protein synthesis inhibition) and is not similar in structure to Pgp or MRP substrates, we postulated that it would be an active agent against therapy-resistant AML. DTctGMCSF was selectively cytotoxic (IC50 1-10ng/ml) to GMCSF-receptor positive AML cells expressing the Pgp- or MRP-associated multi-drug resistant phenotypes, despite high level resistance to conventional chemotherapeutic agents. DTctGMCSF also efficiently killed AML cells deficient in p53 expression, as well as radiation-resistant AML cells and mixed lineage leukemia cells expressing high levels of bcl-2. In addition, DTctGMCSF killed > 99% of primary leukemic progenitor cells from therapy-refractory AML patients under conditions that we have previously found to not adversely affect the proliferative capacity or differentiation of pluripotent normal hematopoietic progenitor cells. DTctGMCSF may prove useful in treating myeloid leukemias that are otherwise resistant to a wide range of conventional therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|